Irene S Kuhn

US Patent:

7510868, Mar 31, 2009

Filed:

May 24, 2005

Appl. No.:

11/136912

Inventors:

Paul Harden - Brentwood CA, US
Terry Hermiston - Corte Madera CA, US
Irene Kuhn - Richmond CA, US

International Classification:

C12N 15/63
A61K 35/00

US Classification:

4353201, 435 911, 435 914, 435 9142, 536 231

Abstract:

The present invention relates to oncolytic adenoviruses having therapeutic applications. Recombinant chimeric adenoviruses, and methods to produce them are provided. The chimeric adenoviruses of the invention comprise nucleic acid sequences derived from adenoviral serotypes classified within the subgroups B through F and demonstrate an enhanced therapeutic index.

US Patent:

8158599, Apr 17, 2012

Filed:

Mar 30, 2009

Appl. No.:

12/413748

Inventors:

Paul Harden - Brentwood CA, US
Terry Hermiston - Corte Madera CA, US
Irene Kuhn - Richmond CA, US

Assignee:

PsiOxus Therapeutics Limited - London

International Classification:

A61K 48/00
C12N 15/00

US Classification:

514 44, 4353201

Abstract:

The present invention relates to oncolytic adenoviruses having therapeutic applications. Recombinant chimeric adenoviruses, and methods to produce them are provided. The chimeric adenoviruses of the invention comprise nucleic acid sequences derived from adenoviral serotypes classified within the subgroups B through F and demonstrate an enhanced therapeutic index.

US Patent:

8216819, Jul 10, 2012

Filed:

Dec 20, 2007

Appl. No.:

12/520538

Inventors:

Terry Hermiston - Corte Madera CA, US
Irene Kuhn - Richmond CA, US

Assignee:

PsiOxus Therapeutics Limited - London

International Classification:

C12N 7/00
A61K 48/00

US Classification:

4352351, 424 933, 514 44

Abstract:

The present invention relates to a method for the production of onolytic adenoviruses having increased potency and their therapeutic applications for cancer. Recombinant adenoviruses and methods to produce them are provided.

US Patent:

20120231524, Sep 13, 2012

Filed:

Apr 10, 2012

Appl. No.:

13/443055

Inventors:

Paul HARDEN - Brentwood CA, US
Terry HERMISTON - Corte Madera CA, US
Irene KUHN - Richmond CA, US

Assignee:

PsiOxus Therapeutics Limited - London

International Classification:

C12N 7/01

US Classification:

4352351

Abstract:

The present invention relates to oncolytic adenoviruses having therapeutic applications. Recombinant chimeric adenoviruses, and methods to produce them are provided. The chimeric adenoviruses of the invention comprise nucleic acid sequences derived from adenoviral serotypes classified within the subgroups B through F and demonstrate an enhanced therapeutic index.

US Patent:

20130209409, Aug 15, 2013

Filed:

Mar 13, 2013

Appl. No.:

13/798784

Inventors:

Paul Harden - Brentwood CA, US
Terry Hermiston - Corte Madera CA, US
Irene Kuhn - Richmond CA, US

International Classification:

C12N 7/00

US Classification:

424 932, 4352351, 435375

Abstract:

The present invention relates to oncolytic adenoviruses having therapeutic applications. Recombinant chimeric adenoviruses, and methods to produce them are provided. The chimeric adenoviruses of the invention comprise nucleic acid sequences derived from adenoviral serotypes classified within the subgroups B through F and demonstrate an enhanced therapeutic index.

US Patent:

20130217095, Aug 22, 2013

Filed:

Apr 15, 2013

Appl. No.:

13/862875

Inventors:

Paul HARDEN - Brentwood CA, US
Terry HERMISTON - Corte Madera CA, US
Irene KUHN - Richmond CA, US

Assignee:

PSIOXUS THERAPEUTICS LIMITED - London

International Classification:

A61K 35/76

US Classification:

4352351

Abstract:

The present invention relates to oncolytic adenoviruses having therapeutic applications. Recombinant chimeric adenoviruses, and methods to produce them are provided. The chimeric adenoviruses of the invention comprise nucleic acid sequences derived from adenoviral serotypes classified within the subgroups B through F and demonstrate an enhanced therapeutic index.

US Patent:

48747050, Oct 17, 1989

Filed:

Dec 6, 1985

Appl. No.:

6/805824

Inventors:

William H. Andrews - Belmont CA
Virginia M. Brothers - Albany CA
James G. Files - Belmont CA
Irene Kuhn - San Francisco CA
Michael T. McCaman - San Bruno CA
Leland S. Paul - Woodside CA
Stacey R. Sias - San Anselmo CA
Thomas C. Gore - Charles City IA
Karel Z. Newman - Clear Lake IA
John L. Tedesco - St. Peters MO

Assignee:

Solvay & Cie, S.A. - Brussels

International Classification:

C12N 120
C12N 1500
C07H 2104

US Classification:

43525233

Abstract:

A genomic DNA molecule having the nucleic acid sequence set forth in FIG. 1 and encoding an antigenic protein derived from Eimeria tenella has been isolated. The protein has a molecular weight of about 25,000 daltons and is composed of two polypeptides joined by a disulfide bond. One of the polypeptides is characterized by a molecular weight of about 17,000 daltons and by a blocked N-terminal amino acid and having the amino acid sequence set forth in FIG. 1. The other polypeptide is characterized by a molecular weight of about 8,000 daltons and has the amino acid sequence set forth in FIG. 1. A cDNA molecule encoding the 25,000 dalton polypeptide with a continuous amino acid sequence has been inserted into expression vectors capable of expressing the 25,000 dalton polypeptide directly or as a fused polypeptide. The polypeptides produced are used in vaccines to immunize chickens against infection by Eimeria tenella.

US Patent:

51870800, Feb 16, 1993

Filed:

Jan 21, 1992

Appl. No.:

7/824700

Inventors:

William H. Andrews - San Mateo CA
Virginia M. Brothers - Albany CA
James G. Files - Belmont CA
Irene Kuhn - San Francisco CA
Michael T. McCaman - San Bruno CA
Stacey R. Sias - San Anselmo CA
Leland S. Paul - Island Lake IL
Thomas C. Gore - Charles City IA
Karel Z. Newman - Eden Prairie MN
John L. Tedesco - St. Peters MO

Assignee:

Solvay & Cie S.A. - Brussels

International Classification:

C12P 2102
C12P 1934
C12N 1500
C12N 700
C12N 121
A61K 3702
C07K 300
C07H 1512

US Classification:

435 693

Abstract:

Nucleic acid molecules are provided which encode antigenic proteins capable of inducing in a chicken an immune response conferring protection against Eimeria tenella. Expression vectors containing the nucleic acid molecules are also provided. Methods for producing the proteins or antigenic polypeptides having amino acid sequences included within these proteins are also provided.